Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mads Daugaard
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
VAR2 Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Project 3 of this NIH funded study seeks to advance a novel technology to gain access to a previously unappreciated and inaccessible malignancy-associated glycosaminoglycan (GAG) component in prostate cancer (PC}. The malaria parasite Plasmodium falciparum has evolved a protein (VAR2CSA) that allows infected human blood cells to bind a GAG structure called chondroitin sulfate (CS) on placental trophoblasts. Placental CS is re-expressed in human PC as a secondary oncofetal CS (ofCS) modification associated with advanced cancer. Oncofetal CS expression is restricted to malignant tissue and highly expressed in PC and castration resistant prostate cancer (CRPC). We believe that we can exploit modified recombinant malarial VAR2CSA proteins (rVAR2) armed with KT886 hemiasterlin compounds
(VDC886) to target PC.
I am a co-discoverer of of CS and the VAR2CSA-based targeting system. VAR2 Pharmaceuticals owns the Intellectual Property of the system. VARCT Diagnostics is a spin-off of VAR2 Pharmaceuticals with an exclusive license to develop the technology. I own founders shares and stock options in both companies.
The Pacific Northwest Prostate Cancer SPORE
PROJECT NARRATIVE Prostate cancer (PC) is a major cause of cancer incidence and mortality in US men. This year alone 180,000 men will be diagnosed and 26,000 will die of the disease; and worldwide, the annual number of men dying from PC is increasing. This highlights the urgent need for translational PC research to uncover the underlying genetic and genomic factors and pathways that drive PC toward its lethal phenotype, including resistance to therapy.
Filed on June 19, 2019.
Tell us what you know about Mads Daugaard's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Mads Daugaard”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Mads Daugaard | Fred Hutchinson Cancer Research Center | Conflict of Interest | VAR2 Pharmaceuticals | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.